Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: Association with increased plasminogen activator inhibitor-1

Metabolism: Clinical and Experimental

Volumn 51, Issue 4, 2002, Pages 471-476

  Aso, Yoshimasa ^a   Matsumoto, Sachiko ^a   Fujiwara, Yukio ^a   Tayama, Kazumi ^a   Inukai, Toshihiko ^a   Takemura, Yoshihiro ^a  

^a DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; FIBRINOGEN; FIBRINOLYTIC FACTOR; GLYCOSYLATED HEMOGLOBIN; PLASMIN ANTIPLASMIN COMPLEX; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC OBESITY; FEMALE; FIBRINOLYSIS; HUMAN; HYPERCOAGULABILITY; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0036117399     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.31334     Document Type: Article

References (35)

1. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study
2. Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: A balanced overview
3. Mortality from coronary heart disease in subjects with type 2 diabetes and nondiabetic subjects and without prior myocardial infarction
4. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients
5. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients
6. The pathogenesis of atherosclerosis; A perspective for 1990s
7. Vascular thrombosis in diabetes
8. Diabetes mellitus as a hypercoagulable state: Its relationship with fibrin fragments and vascular damage
9. Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes
10. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus
11. Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes
12. Activation of blood coagulation and fibrinolysis in diabetes mellitus: Evaluation by plasma levels of thrombin-antithrombin III complex and plasmin-alpha2-plasmin inhibitor complex
13. Fibrinolysis and diabetic retinopathy in NIDDM
14. Plasminogen activator inhibitor-1: A common denominator in cardiovascular
15. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients - Relationship with plasma insulin
16. Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non-insulin-dependent)
17. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis
18. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease
19. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease
20. New definition and diagnostic criteria for obesity in Japanese
21. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: The BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity
22. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects
23. Fibrinogen plasma levels as a marker of thrombin activation in diabetes
24. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators
25. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans
26. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease
27. Blood coagulation and fibrinolysis
28. Plasminogen activator inhibitor 1: Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes
29. Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type-1 by insulin on soluble factors released from vascular smooth muscle cells
30. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis
31. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes
32. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus
33. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2
34. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control
35. Sp1 sites mediate activation of the plasminogen-activator inhibitor-1 promoter by glucose in vascular smooth muscle cells